Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/19/21
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 10/16/20
End: 03/24/22
Due: 03/24/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation | NCT04711226 | Anelixis Therapeutics, LLC | user2@example.com | None | 2021-02-19 | 2026-06-30 | 2027-06-30 | - | - | 2025-07-14 |
| Multiple Doses of AT-1501-A201 in Adults With ALS | NCT04322149 | Anelixis Therapeutics, LLC | user2@example.com | None | 2020-10-16 | 2022-03-24 | 2023-03-24 | - | - | 2025-07-14 |